What is CrossBridge Bio?
CrossBridge Bio, based in Houston, Texas, is a biotechnology firm dedicated to advancing therapeutic options for patients. The company's core mission is to address and overcome the limitations inherent in current Antibody-Drug Conjugates (ADCs), aiming to develop more effective treatments. This focus positions CrossBridge Bio within the highly dynamic and innovation-driven biopharmaceutical sector, where novel approaches to drug delivery and efficacy are paramount.
How much funding has CrossBridge Bio raised?
CrossBridge Bio has raised a total of $10M across 1 funding round:
Other Financing Round
$10M
Other Financing Round (2024): $10M with participation from TMC Venture Fund, Alexandria Venture Investments LLC Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and CE-Ventures
Key Investors in CrossBridge Bio
Alexandria Venture Investments LLC Alexandria Venture Investments
Alexandria Venture Investments LLC Alexandria Venture Investments is a venture capital firm that operates in the early-stage investment space, likely focusing on companies with high growth potential in the life sciences sector.
Portal Innovations
Portal Innovations is a venture development engine and life sciences venture capital firm that supports early-stage biotech and medtech startups by providing capital, lab space, and strategic guidance to foster company growth.
TMC Venture Fund
TMC Venture Fund is an investment entity that participates in funding rounds for companies, likely within the healthcare or biotechnology sectors, given its association with CrossBridge Bio.
What's next for CrossBridge Bio?
With the recent major strategic investment, CrossBridge Bio is poised for an accelerated growth phase. The capital infusion is expected to fuel further research and development, potentially leading to the advancement of its ADC platform through clinical trials and towards commercialization. The company's strategic focus on improving upon existing ADC technologies suggests a commitment to addressing unmet medical needs, which could attract further investment and partnerships as it progresses through its development lifecycle. This funding round, characterized as enterprise-level, indicates strong confidence from investors in CrossBridge Bio's long-term vision and its capacity to deliver impactful therapeutics.
See full CrossBridge Bio company page
